The Medicines Co., of Parsippany, N.J., posted worldwide net revenue of $72.7 million for the third quarter. Sales of Angiomax/Angiox (bivalirudin) reached $47 million, down from the $151 million in sales recorded for the same quarter in 2014, largely driven by the loss of exclusivity.